New Studies Published on SDH Models and GIST Research
Two new studies were published in July and August 2021 focusing on SDH-deficient tumor models and how location can affect GIST tumor profiles and drug sensitivity.
Actualización realizada por dos prestigiosos especialistas internacionales en GIST
Publicado por Colectivo GIST España - Concluimos el mes dedicado a la concienciación del sarcoma & GIST publicando una actualización del tratamiento para los tumores GIST avanzados.
Q&A with SDH Panel of Experts Yields Promise for the SDH-deficient GIST Community
The Life Raft Group celebrated GIST Awareness Day 2021 by holding an virtual, interactive Q&A session for SDH-deficient GIST patients with leading experts in the field.
Calling All GEMs!
Become a GEM today! Help us continue our programs and services for GIST patients by giving a monthly recurring donation. Every little bit helps us to further research and support GIST patients and caregivers.
Heroes of Rare Disease: The 2021 Rare Impact Awards
June 28th Awards Ceremony registration: https://livingrare.org/rare-impact-awards/ Dr. Jason Sicklick, Blueprint Medicines Among Honorees Released 2/23/21 by NORD The National Organization for Rare Disorders (NORD®) announced this year’s Rare Impact Award honorees. These outstanding [...]
Dr. Thomas Mühlenberg Receives 2020 GIST Award
The 2020 GIST award goes to Dr. Thomas Mühlenberg of the University of Duisburg-Essen The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST), has awarded its science prize for [...]
Life Raft Group Participates in Virtual CTOS Conference
The annual meeting of CTOS (Connective Tissue Oncology Society) will be held virtually this year due to the global pandemic.
Dr. Gina D’Amato Discusses Liquid Biopsy
Dr. Gina D'Amato, who appeared recently as moderator and contributor for the first Women in Sarcoma discussion panel, recorded a video discussing the use of liquid biopsy in sarcoma on OncTV for OncLive.
Pruebas genéticas costo efectivas para GIST recién diagnosticados
En un artículo publicado el 29 de septiembre de 2020 en la revista “JAMA Network Open”, Dr. Jason Sicklick, Moores Cancer Center, UCSD y sus colegas informaron que las pruebas genéticas son costo efectivas y beneficiosas para los pacientes recién diagnosticados con GIST metastásico.
Genetic Testing Cost Effective for Newly Diagnosed GIST
UC San Diego Health released a post today titled, "Genetic Testing Cost Effective for Newly Diagnosed GIST" discussing a new paper published in JAMA Network Open by Moores Cancer Center's Dr. Jason Sicklick and colleagues which covered genetic testing for GIST patients.